Oxford Biomedica, a major contract manufacturer for cell and gene therapies, confirmed takeover talks with private equity investor EQT after rejecting multiple bids it deemed to undervalue the company. The discussions underscore continued strategic interest in CDMO and CMO assets amid supply‑chain reshoring and growing demand for gene‑therapy manufacturing capacity. Analysts note the deal rationale leans on Oxford’s process know‑how and capacity, which are increasingly scarce as more developers move toward clinical and commercial cell and gene therapy programs.